• en
    • de

+49 30 5557999 -30


Diabetes and arteriosclerosis, a global problem

BelDIA PRE, BelACT – Part of our strategy against diseases No. 1

PharmACT’s team of experts is working on the development, manufacture and marketing of a new drug for the effective reduction of arteriosclerotic plaque.

PharmACT’s Board of Trustees is available to support the establishment of local academies, also to transport our services to organisations and industry.

The results from the area of research and development have now been transferred to the task of approving and conducting clinical trials. Registration ensures that the BelACT® therapy is registered.

Research institutions in Spain, Morocco and Russia have been involved in order to obtain approval of the planned drug from the European Medicine Agency.

 

 

IVD – BelDIA PRE®

BelDIA PRE® is a point-of-care (POCT) test that detects the personal risk of developing type 2 diabetes and/or arteriosclerosis. In just 20 minutes, you’ll know the answer to developing type 2 diabetes. If the test is positive, you have up to 24 months to prevent diabetes mellitus. Ask your doctor!

 

Type 2 diabetes recognized 24 months in advance.

Heilung

IVD – BelCARDIO®

With BelCARDIO®, PharmACT provides another POCT for physicians and healthcare professionals that shows after 10 minutes whether your patient has recently suffered a myocardial infarction or whether there is a different indication. With BelCARDIO you filter out the approximately 20% of patients with chest pain who have suffered acute myocardial infarction.

10-minute rapid test to detect infarcts.

Health Region Berlin-Brandenburg

The health region Berlin-Brandenburg has nationally and internationally recognised medical facilities as well as excellent university and non-university research centres. Numerous small and medium-sized companies from the sectors “biotechnology/pharmaceuticals”,”medical technology”,”new forms of care and rehabilitation” and “health promotion/prevention” have their locations in the capital region. All in all, these are very good prerequisites for the international success of PharmACT AG with its high innovation and growth potential.

Additional Information…

patienten

You are a medical specialist and want to make your arteriosclerosis patients worth living again? Talk to us today, perhaps you would like to support our clinical studies?

Get involved